218 related articles for article (PubMed ID: 22727039)
1. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Riddle JL; Rokosik SL; Napier TC
Behav Brain Res; 2012 Jul; 233(1):15-23. PubMed ID: 22727039
[TBL] [Abstract][Full Text] [Related]
2. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
[TBL] [Abstract][Full Text] [Related]
3. Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson's disease and controls.
Rokosik SL; Napier TC
Neuropsychopharmacology; 2012 May; 37(6):1397-408. PubMed ID: 22257895
[TBL] [Abstract][Full Text] [Related]
4. Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2013 Sep; 252():24-31. PubMed ID: 23727149
[TBL] [Abstract][Full Text] [Related]
5. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
[TBL] [Abstract][Full Text] [Related]
7. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
Willis GL
Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
[TBL] [Abstract][Full Text] [Related]
9. Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.
Loiodice S; McGhan P; Gryshkova V; Fleurance R; Dardou D; Hafidi A; Nogueira da Costa A; Durif F
J Psychopharmacol; 2017 Oct; 31(10):1323-1333. PubMed ID: 28631520
[TBL] [Abstract][Full Text] [Related]
10. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
11. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Delgado-Alvarado M; Navalpotro-Gómez I; Belloso-Iguerategui A; Marin C; Rodríguez-Oroz MC
Psychopharmacology (Berl); 2020 Aug; 237(8):2419-2431. PubMed ID: 32440779
[TBL] [Abstract][Full Text] [Related]
12. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
14. Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2014 Apr; 262():1-7. PubMed ID: 24361908
[TBL] [Abstract][Full Text] [Related]
15. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Lane EL; Cheetham SC; Jenner P
Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
[TBL] [Abstract][Full Text] [Related]
16. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of 5-HT6 receptors in the nucleus accumbens blocks the rewarding but not psychomotor activating properties of cocaine.
Ferguson SM; Mitchell ES; Neumaier JF
Biol Psychiatry; 2008 Jan; 63(2):207-13. PubMed ID: 17631868
[TBL] [Abstract][Full Text] [Related]
19. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
Harvey BK; Mark A; Chou J; Chen GJ; Hoffer BJ; Wang Y
Brain Res; 2004 Oct; 1022(1-2):88-95. PubMed ID: 15353217
[TBL] [Abstract][Full Text] [Related]
20. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
